Fatty acid synthase (FASN) and ATP-citrate lyase, key enzymes of de novo lipogenesis, are
significantly upregulated and activated in many cancers and portend poor prognosis. Even …

Metabolic interaction between cancer-associated fibroblasts (CAFs) and colorectal cancer
(CRC) cells plays a major role in CRC progression. However, little is known about lipid …

Fatty acid synthase (FASN), a lipogenic enzyme, is upregulated in colorectal cancer (CRC).
Increased de novo lipid synthesis is thought to be a metabolic adaptation of cancer cells that …

Upregulation of fatty acid synthase (FASN), a key enzyme of de novo lipogenesis, is
associated with metastasis in colorectal cancer (CRC). However, the mechanisms of …

Objective In the present study, we aimed to investigate the potential role of fatty acid
synthase (FASN) in the development and progression of colorectal cancer (CRC). Materials …

Fatty acid synthase, a key enzyme of de novo lipogenesis, is an attractive therapeutic target
in cancer. The novel fatty acid synthase inhibitor, TVB-3664, shows anti-cancer activity in …

Fatty acid synthase (FASN) is the terminal enzyme in de novo lipogenesis and plays a key
role in cell proliferation. Pharmacologic inhibitors of FASN are being evaluated in clinical …

Hepatocellular carcinoma (HCC) is one of the most common solid tumors worldwide,
characterized by clinical aggressiveness, resistance to conventional chemotherapy, and …

Fatty acid synthase (Fasn) is the key metabolic enzyme that accounts for the terminal
catalytic step in fatty acid synthesis, which is hyperactivated in various tumors. In this study …

Inhibition of de novo palmitate synthesis via fatty acid synthase (FASN) inhibition provides
an unproven approach to cancer therapy with a strong biological rationale. FASN …